HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Hydroxychloroquine and Azithromycin as Treatments for COVID-19

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.12996/gmj.2020.82


Title: Hydroxychloroquine and Azithromycin as Treatments for COVID-19
Authors: Ohe, Masashi Browse this author
Furuya, Ken Browse this author
Goudarzi, Houman Browse this author →KAKEN DB
Keywords: COVID-19
SARS-CoV-2
Hydroxychloroquine
Macrolide
Azithromycin
Issue Date: 19-May-2020
Publisher: Gazi University
Journal Title: Gazi Medical Journal
Volume: 31
Issue: 2A
Publisher DOI: 10.12996/gmj.2020.82
Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that originated in late 2019 and continues to spread as of 2020 is taking a severe toll on human health and has been acknowledged as a worldwide pandemic. There have been no readily available vaccines or drugs that have been approved to combat the disease (COVID-19) as of yet. Chloroquine (CQ), a drug well-known for its effectiveness in treating malarial and autoimmune disease such as rheumatoid arthritis and lupus erythematosus, has exhibited a promising inhibitory effect for SARS-CoV-2. Hydroxychloroquine (HCQ), a more tolerable derivative of CQ, has also been shown to display potent activity against SARS-CoV-2. Macrolides (MACs) such as erythromycin, clarithromycin, and azithromycin (AZM) not only have the potential for anti-bacterial activity but also have immunomodulatory effects. Lately, the anti-viral effects of MACs have attracted considerable attention. Very recently, HCQ in combination with AZM treatment was reported to be effective for mild form of COVID-19. Because mild form of COVID-19 may take a turn for the worse, resulting in acute respiratory distress syndrome, or mild COVID-19 patients may infect surrounding people with COVID-19, patients should be treated with HCQ in combination with AZM.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/79157
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University